23 years of historical data (2003–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Corcept Therapeutics Incorporated trades at 43.5x earnings, 33% above its 5-year average of 32.7x, sitting at the 90th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 84%. On a free-cash-flow basis, the stock trades at 26.7x P/FCF, 10% above the 5-year average of 24.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.8B | $4.2B | $5.7B | $3.6B | $2.4B | $2.5B | $3.2B | $1.5B | $1.7B | $2.2B | $843M |
| Enterprise Value | $3.7B | $4.1B | $5.6B | $3.5B | $2.3B | $2.4B | $3.2B | $1.5B | $1.5B | $2.1B | $806M |
| P/E Ratio → | 43.54 | 42.44 | 40.97 | 34.55 | 23.34 | 22.25 | 30.78 | 15.71 | 22.27 | 17.37 | 103.71 |
| P/S Ratio | 4.97 | 5.48 | 8.47 | 7.52 | 5.86 | 6.81 | 9.18 | 4.84 | 6.74 | 14.13 | 10.37 |
| P/B Ratio | 6.61 | 6.45 | 8.41 | 7.16 | 4.69 | 6.64 | 6.21 | 4.00 | 6.14 | 11.78 | 20.38 |
| P/FCF | 26.68 | 29.45 | 29.19 | 28.60 | 19.64 | 14.90 | 21.55 | 10.98 | 14.67 | 37.16 | 46.34 |
| P/OCF | 26.64 | 29.41 | 28.87 | 28.57 | 19.57 | 14.86 | 21.38 | 10.90 | 14.63 | 36.90 | 45.85 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Corcept Therapeutics Incorporated's enterprise value stands at 78.6x EBITDA, 98% above its 5-year average of 39.8x. The Healthcare sector median is 13.8x, placing the stock at a 468% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.33 | 8.29 | 7.24 | 5.70 | 6.60 | 8.97 | 4.75 | 5.91 | 13.47 | 9.91 |
| EV / EBITDA | 78.58 | 86.99 | 40.48 | 32.25 | 20.11 | 18.95 | 24.34 | 12.79 | 16.56 | 40.50 | 78.54 |
| EV / EBIT | 81.89 | 61.10 | 40.87 | 32.57 | 20.33 | 19.33 | 24.77 | 13.04 | 16.60 | 40.58 | 80.08 |
| EV / FCF | — | 28.64 | 28.57 | 27.53 | 19.10 | 14.44 | 21.07 | 10.78 | 12.88 | 35.44 | 44.31 |
Margins and return-on-capital ratios measuring operating efficiency
Corcept Therapeutics Incorporated earns an operating margin of 5.9%. Operating margins have compressed from 22.2% to 5.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 15.0% indicates solid capital efficiency. ROIC of 6.2% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating Margin | 5.9% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net Profit Margin | 13.1% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | 15.0% | 23.6% | 21.0% | 23.1% | 25.0% | 23.7% | 29.1% | 32.3% | 111.1% | 27.2% |
| ROA | 11.9% | 11.9% | 19.1% | 17.6% | 20.1% | 22.6% | 21.5% | 26.0% | 28.3% | 89.3% | 13.5% |
| ROIC | 6.2% | 6.2% | 22.1% | 19.9% | 23.0% | 24.9% | 24.2% | 40.6% | 86.0% | 86.7% | — |
| ROCE | 6.5% | 6.5% | 22.5% | 20.9% | 25.4% | 27.6% | 28.6% | 34.4% | 38.3% | 45.5% | 28.1% |
Solvency and debt-coverage ratios — lower is generally safer
Corcept Therapeutics Incorporated carries a Debt/EBITDA ratio of 0.1x, which is very conservative (96% below the sector average of 3.1x). The company holds a net cash position — cash of $120M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | 0.35 |
| Debt / EBITDA | 0.13 | 0.13 | 0.05 | 0.00 | 0.01 | 0.00 | 0.02 | 0.03 | — | — | 1.43 |
| Net Debt / Equity | — | -0.18 | -0.18 | -0.27 | -0.13 | -0.21 | -0.14 | -0.07 | -0.75 | -0.54 | -0.89 |
| Net Debt / EBITDA | -2.45 | -2.45 | -0.87 | -1.25 | -0.57 | -0.60 | -0.56 | -0.24 | -2.30 | -1.96 | -3.59 |
| Debt / FCF | — | -0.81 | -0.62 | -1.07 | -0.54 | -0.46 | -0.49 | -0.21 | -1.79 | -1.72 | -2.03 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | 1078.67 | 4.99 |
Net cash position: cash ($120M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
Corcept Therapeutics Incorporated's current ratio of 2.92x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.39x to 2.92x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.07 | 7.91 | 6.72 | 4.75 | 2.40 |
| Quick Ratio | 2.85 | 2.85 | 3.26 | 4.31 | 6.80 | 5.50 | 9.97 | 7.77 | 6.26 | 4.47 | 2.31 |
| Cash Ratio | 2.24 | 2.24 | 2.72 | 3.52 | 5.95 | 4.70 | 9.28 | 7.10 | 5.77 | 3.52 | 1.88 |
| Asset Turnover | — | 0.91 | 0.80 | 0.78 | 0.69 | 0.86 | 0.62 | 0.74 | 0.81 | 0.72 | 1.18 |
| Inventory Turnover | 1.01 | 1.01 | 0.88 | 0.84 | 0.88 | 1.06 | 1.14 | 1.01 | 0.32 | 0.42 | 0.88 |
| Days Sales Outstanding | — | 28.66 | 31.40 | 43.00 | 42.56 | 28.95 | 27.02 | 23.73 | 25.55 | 64.64 | 44.26 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Corcept Therapeutics Incorporated returns 6.5% to shareholders annually primarily through share buybacks. The earnings yield of 2.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | 2.4% | 2.4% | 2.9% | 4.3% | 4.5% | 3.2% | 6.4% | 4.5% | 5.8% | 1.0% |
| FCF Yield | 3.7% | 3.4% | 3.4% | 3.5% | 5.1% | 6.7% | 4.6% | 9.1% | 6.8% | 2.7% | 2.2% |
| Buyback Yield | 6.5% | 5.9% | 0.3% | 4.0% | 0.0% | 11.9% | 0.3% | 2.1% | 1.4% | 0.0% | 0.0% |
| Total Shareholder Yield | 6.5% | 5.9% | 0.3% | 4.0% | 0.0% | 11.9% | 0.3% | 2.1% | 1.4% | 0.0% | 0.0% |
| Shares Outstanding | — | $120M | $113M | $112M | $116M | $126M | $124M | $123M | $127M | $125M | $116M |
Compare CORT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CORTYou | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CORT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonCorcept Therapeutics Incorporated's current P/E ratio is 43.5x. The historical average is 35.3x. This places it at the 90th percentile of its historical range.
Corcept Therapeutics Incorporated's current EV/EBITDA is 78.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 37.2x.
Corcept Therapeutics Incorporated's return on equity (ROE) is 15.0%. The historical average is -53.6%.
Based on historical data, Corcept Therapeutics Incorporated is trading at a P/E of 43.5x. This is at the 90th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Corcept Therapeutics Incorporated has 98.3% gross margin and 5.9% operating margin.
Corcept Therapeutics Incorporated's Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.